-
21
Descriptive statistics and demographics of study participants, Ukunda and Kisumu sites, Kenya, Dec 2019–Feb 2022.
Foilsithe / Cruthaithe 2025Ábhair: -
22
-
23
-
24
Univariate analysis between DENV and CHIKV seropositivity and selected risk factors.
Foilsithe / Cruthaithe 2025Ábhair: -
25
Seroconversion of DENV and CHIKV among study participants in Kisumu and Ukunda, Kenya, Dec 2019 – Feb 2022.
Foilsithe / Cruthaithe 2025Ábhair: -
26
Stratification of Liver Stiffness according to eGFR in the MAFLD group.
Foilsithe / Cruthaithe 2025Ábhair: -
27
Kaplan Meier survival curves for new CHIKV seropositivity during the 2- year study period from Dec 2019 – Feb 2022.
Foilsithe / Cruthaithe 2025Ábhair: -
28
Kaplan Meier survival curves for new DENV seropositivity during the 2-year study period from Dec 2019 – Feb 2022..
Foilsithe / Cruthaithe 2025Ábhair: -
29
Medication-inclusive multivariable logistic regression for MAFLD.
Foilsithe / Cruthaithe 2025Ábhair: -
30
Receiver operating characteristic (ROC) curve analysis comparing the performance of non-invasive fibrosis scores in MAFLD patients.
Foilsithe / Cruthaithe 2025Ábhair: -
31
-
32
A. Violin plots showing eGFR distribution in MAFLD (red) vs. non-MAFLD (blue) groups.
Foilsithe / Cruthaithe 2025Ábhair: -
33
-
34
Multivariate analysis between DENV and CHIKV seropositivity and selected risk factors.
Foilsithe / Cruthaithe 2025Ábhair: -
35
-
36
Univariate analysis between DENV and CHIKV seroconversion and selected risk factors.
Foilsithe / Cruthaithe 2025Ábhair: -
37
2D–shear-wave elastography example: MAFLD + CKD case (female, 57 years).
Foilsithe / Cruthaithe 2025Ábhair: -
38
Grades of liver fibrosis in MAFLD group (grey) and non-MAFLD group (black).
Foilsithe / Cruthaithe 2025Ábhair: -
39
Distribution of DENV and CHIKV seroprevalence by age group of participants in the study.
Foilsithe / Cruthaithe 2025Ábhair: -
40